[Chinese expert consensus on epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer (2025 edition)].

In recent years, with the discovery of epidermal growth factor receptor (EGFR) gene and the successful development of tyrosine kinase inhibitors (TKI), the treatment efficacy for non-small cell lung cancer (NSCLC) patients with EGFR gene sensitive mutation has been greatly improved. With the increasing variety of EGFR-TKI approved for marketing subsequently, it brings confusion to clinicians when choosing specific medications, and there is an urgent need to develop relevant treatment guidelines. Hence, based on the "China clinical practice guideline for epidermal growth factor receptor tyrosine kinase inhibitors in stage Ⅳ non-small cell lung cancer (version 2023)", the Medical Oncology Branch of China International Exchange Promotive Association for Medical and Health Care and the Chinese Association for Clinical Oncologists organized experts to integrate the research results of various EGFR-TKI, and proposed the " Chinese expert consensus on epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer (2025 edition)", the recommendations have been updated and enriched based on the latest clinical evidence to provide reference for better clinical practice.